Endocrine Abstracts

This study presents epidemiological data of 1512 Italian acromegalic patients who had been diagnosed from 1980 to 2002 and followed-up for more than 10 years, retrospectively collected by 24 tertiary referral centers. Data on co-morbidities and mortality were compared to those of the general Italian population obtained by the Italian National Institute of Statistic. At diagnosis median age of patients (41% M, 59% F) was 46 years, GH (mean±S.D.) 31±37 m...

Introduction: Patients with craniopharyngeoma often have disturbances of the hypothalamic–pituitary axis and serious comorbidities as obesity. We hypothesized, that the pattern of hormones regulating the nutritional status is worsened in adult patients with craniopharyngioma (CP) compared to adult patients with non-functioning pituitary adenoma (NFPA).Methods: We included 33 patients with CP (m=16, f=17, median age: 48 years (26–7...

Background: Hypercalciuria is frequent in patients with acromegaly, but it is unclear how GH/insulin-like growth factor 1 (IGF1) regulate renal calcium handling. Elevated fasting plasma calcium levels despite increased glomerular filtration suggest enhanced renal calcium reabsorption.Objective: To investigate the impact of acromegaly on phosphocalcium metabolism.Design: Prospective sequential study (ClinicalTrials.gov Identifier: N...

Introduction: Current treatment guidelines for patients with insufficiency of the hypothalamic pituitary adrenal (HPA) axis recommend weight adjusted glucocorticoid supplementation doses to minimize risk of negative side effects (e.g. osteoporosis etc).However, little is known on a potential dose-dependent effect of glucocorticoid supplementation on overall mortality in patients with pituitary disease. Non-functioning pituitary adenoma (NFPA) is one of t...

Objective: GH replacement therapy currently requires daily injections, which may cause poor compliance and distress for patients. CTP-modified hGH (MOD-4023) is being developed for once-weekly administration in GH Deficient adults and children. The present study evaluated the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of MOD-4023 in GHD adults.Design and methods: 39 normalized GHDA patients currently treated with daily GH were randomized and...

Introduction: The relation between GH treatment and cancer is still matter of debate. Childhood cancer survivors (CCS) have a high risk to develop second benign and malignant neoplasms (SNs), mainly as a consequence of radiation therapy. Thus, in patients with GH deficiency it is difficult to discriminate the oncological risk due to GH treatment from that caused by anticancer therapy and by individual susceptibility.Methods: We studied the prevalence of ...